Formulation Development
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
Fate Therapeutics, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen…
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
4D Molecular Therapeutics recently announced the US FDA has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in….
Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
Starton Therapeutics Inc. recently announced it has received a Clinical Trial Authorization (CTA) in the Netherlands to initiate a Phase 1 study evaluating STAR-LLD bioavailability in….
Wheeler Bio Announces $14-Million Seed Round to Expand Access to Portable CMC
Wheeler Bio, a biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact, recently announced the closing of a $14-million Seed financing…
Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types & in Diabetes for BMF-219
Biomea Fusion, Inc. recently announced that in 2022 it plans to initiate clinical studies to dose its irreversible covalent menin inhibitor, BMF-219, in up to…
Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
Veru Inc. recently announced the US FDA has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm, a selective androgen receptor targeting agonist, for the treatment of….
Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell & Gene Therapy Platform
Castle Creek Biosciences, Inc. recently announced it has acquired Novavita Thera, Inc., a preclinical gene therapy company focused on rare liver and metabolic diseases. The…
Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer
Adare Pharma Solutions recently announced the appointment of Tom Sellig as Chief Executive Officer (CEO). Sellig, a 30-year veteran of the pharmaceutical and life sciences industries, will lead the….
Eisai Enters Into Exclusive Licensing Agreement With Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
Eisai Co., Ltd. recently announced it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the…
Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Sosei Heptares & Verily to Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases
Sosei Group Corporation and Verily recently announced they have entered into a strategic research collaboration. The research agreement brings together the….
Biomea Fusion Releases Preclinical Data With BMF-219 in Diabetes
Biomea Fusion, Inc. recently announced BMF-219 displayed remarkable activity in both the Zucker Diabetic Fatty (ZDF) Rat and the Streptozotocin-Induced Diabetes (STZ) animal models of…
Aceragen Announces $3.5-Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations
Aceragen, Inc. recently announced that its wholly owned subsidiary, Arrevus, Inc., has received an award from the Cystic Fibrosis Foundation for up to $3.5 million…
Moderna Announces First Participant Dosed in Phase 1 Study of its Epstein-Bar Virus Vaccine
Moderna, Inc. recently announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus (EBV) vaccine candidate. The study…
PhoreMost & POLARISqb Announce a Multi-Target Collaboration to Investigate Next-Generation Cancer Therapies
PhoreMost Limited and Polaris Quantum Biotech recently announced a collaboration to study oncology targets currently considered undruggable. Under the terms of the agreement, the POLARISqb…
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind Corporation recently announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of….
Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….
Akoya Biosciences & Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow With Industry-Leading Speed & Resolution
Akoya Biosciences, Inc. and Bio-Techne recently announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through…
Rain Therapeutics & Roche to Collaborate on Clinical Trial of Milademetan Combination With Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
Rain Therapeutics Inc. recently announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab…..
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
F-star Therapeutics, Inc. recently announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany, has exercised a fourth licensing option to develop another…
2025 - 5 - Gattefosse - 250x250